Unknown

Dataset Information

0

CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.


ABSTRACT: Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt's lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specific biomarkers for lymphoma is of high clinical significance. Herein, a potential marker, CD38, is investigated for differentiating lymphoma. A CD38-targeting monoclonal antibody (mAb, daratumumab) is then radiolabeled with Zr-89 and Lu-177 for theranostic applications. As the diagnostic component, the Zr-89-labeled mAb is highly specific in delineating CD38-positive lymphoma via positron emission tomography (PET) imaging, while the Lu-177-labeled mAb serves well as the therapeutic component to suppress tumor growth after a one-time administration. These results strongly suggest that CD38 is a lymphoma-specific marker and prove that 89Zr/177Lu-labeled daratumumab facilitates immunoPET imaging and radioimmunotherapy of lymphoma in preclinical models. Further clinical evaluation and translation of this CD38-targeted theranostics may be of significant help in lymphoma patient stratification and management.

SUBMITTER: Kang L 

PROVIDER: S-EPMC8132161 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5807532 | biostudies-literature
| S-EPMC9012778 | biostudies-literature
| S-EPMC7736260 | biostudies-literature
| S-EPMC5700843 | biostudies-literature
| S-EPMC8940612 | biostudies-literature
| S-EPMC8068522 | biostudies-literature
| S-EPMC9160799 | biostudies-literature
| S-EPMC10570397 | biostudies-literature
| S-EPMC10308590 | biostudies-literature
| S-EPMC7785666 | biostudies-literature